Company intelligence / Profile preview

Mindbloom

Orlando, Florida, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Mindbloom has published the largest-ever clinical studies for at-home psychedelic therapy, showing that 62% of clients experience significant improvements in depression or anxiety after four ketamine sessions, with a strong safety profile and sustained benefits reported with maintenance therapy.

Therapeutic areas: Psychiatry
Modalities: Small moleculeDeviceNon-pharmacological therapy
Industry: Non-Academic Healthcare

Partnerships

Happier (mindfulness collaboration)

Beyond the preview

Go deeper on Mindbloom.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mindbloom.

Explore the full profile